A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).

被引：0
|
作者：
Berdeja, Jesus G.
Martin, Thomas G.
Rossi, Adriana
Essell, James H.
Siegel, David Samuel DiCapua
Mailankody, Sham
Saini, Neeraj
Holmes, Houston
Dhakal, Binod
Gasparetto, Cristina J.
Parekh, Samir S.
Portella, Socorro
Ledergor, Guy
Hammad, Ashley
Davi, Franco
Skoble, Justin
Garner, Elizabeth
Kanner, Steven Brian
Rizvi, Syed
Jagannath, Sundar
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Univ Calif San Francisco, Dept Hematol, San Francisco, CA USA
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] Onc Hem Care Inc, Cincinnati, OH USA
[5] Hackensack Meridian Hlth, Ctr Discovery & Innovat, Nutley, NJ USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY USA
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[8] Texas Oncol, Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[9] Med Coll Wisconsin, Milwaukee, WI USA
[10] Duke Univ, Inst Canc, Dept Med, Durham, NC USA
[11] Caribou Biosci, Berkeley, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8063
引用
收藏
页数：1
相关论文
共 23 条
  • [21] HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma
    Schade, Henning
    Madan, Sumit
    Medvedova, Eva
    Nath, Rajneesh
    Knapp, Lisa
    Lemon, Bryan
    Sun, Liping Laura
    BLOOD, 2020, 136
  • [22] A Phase 1, Multicenter, Open-Label Study to Establish the Preliminary Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process, for Severe, Refractory Autoimmune Diseases
    Schett, Georg
    Littlejohn, Emily
    Kramer, Neil
    Saxena, Amit
    Mease, Philip
    Wiesendanger, Margrit
    Mueller, Fabian
    Reshef, Ran
    Caimi, Paolo
    Cherry, Mohamad
    Hsu, Jingmei
    Patel, Krish
    Azzi, Jacques
    Falcon, Susana
    Ly, Thomas
    Ogasawara, Ken
    Das, Sharmila
    Thorpe, Jerill
    Maldonado, Michael
    Stifano, Giuseppina
    Koegel, Ashley
    Askanase, Anca
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 3580 - 3582
  • [23] Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
    Bal, Susan
    Kocoglu, M. Hakan
    Nadeem, Omar
    Htut, Myo
    Gregory, Tara
    Anderson, Larry D., Jr.
    Costa, Luciano J.
    Buchholz, Tonia J.
    Ziyad, Safiyyah
    Li, Meng
    Chen, Yanping
    Kaeding, Allison J.
    Burgess, Michael R.
    Hege, Kristen
    Berdeja, Jesus
    BLOOD, 2022, 140
123